Skip to main content
. 2023 Mar 28;9(4):763–776. doi: 10.1021/acscentsci.2c01465

Figure 1.

Figure 1

Bioreductive prodrugs. (a) Chemotypes used for bioreductive clinical prodrugs: (i) aliphatic N-oxides, (ii) aromatic N-oxides, and (iii) nitroimidazoles and nitroaromatics. (b) Bicyclic disulfides targeting the Trx/TrxR system, one of the new motifs for bioreductive prodrug development introduced in this paper.